Is Ionis Pharmaceuticals, Inc. (IONS) Stock a Buy After Tryngolza’s FDA Approval?
TheFly reported on June 25 that H.C. Wainwright increased its price target on IONS to $130 from $125 while maintaining a Buy rating on the shares. The revision followed the U.S.








